Anthera Announces Completion of Phase 2b PEARL-SC; AstraZeneca/The Medicines Company Announce Global Collaboration Print E-mail
By Staff and Wire Reports   
Wednesday, 25 April 2012 18:54
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 25, 2012.

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH)
announced the completion of dosing in the Company's Phase 2b PEARL-SC study. PEARL-SC (A randomized, double-blind Phase 2b study to evaluate the efficacy, safety, and tolerability of blisibimod administration in subjects with systemic lupus erythematosus) is examining the therapeutic benefit of monthly and weekly subcutaneous administration of blisibimod in systemic lupus erythematosus (SLE) patients.

The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in an SLE responder index (SRI)-- a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI* improvement of 5 points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two or more new BILAG B organ domain scores.



=====



AstraZeneca (NYSE: AZN)
and The Medicines Company (NASDAQ: MDCO) announced a global collaboration for acute ischemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca's oral antiplatelet medicine BRILINTA® (ticagrelor) tablets.

Under the terms of the co-promotion agreement, The Medicines Company sales force will begin supporting BRILINTA in May 2012. This will complement the AstraZeneca sales team's promotion of BRILINTA to US hospital customers and practitioners whose patients with acute coronary syndrome (ACS) may benefit from this important therapy.




Also Wednesday:




Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today presented data showing that the increase in walking speed demonstrated by people with multiple sclerosis (MS) who responded to treatment with AMPYRA® during three-month Phase 3 clinical trials was also observed for up to five years in open-label extension studies.

Advaxis, Inc., (OTCBB: ADXS)
, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Dr. John Rothman, EVP of Science & Operations at Advaxis, will be chairing and speaking at the morning session of the 2012 World Immunotherapy Online Symposium Series, produced by Target Meeting, on April 27, 2012 at 9am EST.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Wednesday, May 9, 2012.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
today announced that its first quarter 2012 financial results will be released on Monday, May 7, 2012. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company’s programs.

BioLineRx (NASDAQ: BLRX) (TASE: BLRX)
, a biopharmaceutical development company, announced today that an Issue Notification has been received from the United States Patent and Trademark Office (USPTO) granting 1,787 days of Patent Term Adjustment for the patent claiming the composition of BCM (BL-1040), a novel medical device for prevention of cardiac remodeling following an acute myocardial infarction.

Fortinet (NASDAQ: FTNT)
, a leader in high-performance network security, and Gilead Sciences, Inc. (NASDAQ: GILD), a leading biopharmaceutical company, received 2012 GROW! Awards from ACG Silicon Valley at a sold-out ceremony with 81 CEOs and over 200 other Valley executives in attendance.

GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced the FDA clearance and availability of the latest version of its Vivid E9™ cardiovascular ultrasound system.

GTx, Inc. (NASDAQ: GTXI)
today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's first quarter 2012 financial results on Tuesday, May 8 at 9:00 a.m. Eastern.

Illumina, Inc. (NASDAQ:ILMN)
today introduced BaseSpace Apps, a dedicated applications store for BaseSpace, the Company’s genomics cloud computing platform.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB)
, a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Thomas Tulip, Navidea’s EVP and Chief Business Officer, was invited to present at two Alzheimer’s Disease (AD) conferences: Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board meeting and the German Nuclear Medicine Convention.

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their overallotment option to purchase an additional 900,000 shares of common stock at the public offering price of $9.75 per share, less underwriting discounts and commissions.

Repligen Corporation (NASDAQ:RGEN)
today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and Progenics Pharmaceuticals (NASDAQ: PGNX) today announced that the Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the Agency’s review of the Supplemental New Drug Application (sNDA) for RELISTOR® (methylnaltrexone bromide) injection for subcutaneous use for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.

SurModics, Inc. (Nasdaq: SRDX)
, a leading provider of surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter 2012 conference call on Tuesday, May 8, at 4:00 p.m. CT.

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced a reduction in force as part of a strategic plan to focus the company’s resources on its clinical programs and select preclinical opportunities.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 31, 2012.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter